An 225Ac/213Bi generator system for therapeutic clinical applications: Construction and operation

Applied Radiation and Isotopes

Volumn 50, Issue 5, 1999, Pages 895-904

  McDevitt, Michael R ^a   Finn, Ronald D ^a   Sgouros, George ^a   Ma, Dangshe ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

213Bi; 213Bi generator; 225Ac; Alpha particle emitting radionuclide; Radioimmunotherapy

Indexed keywords

ALPHA RADIATION; ANTIBODY LABELING; ARTICLE; ISOTOPE LABELING; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PROTECTION; INSTRUMENTATION; METHODOLOGY; NUCLEAR MEDICINE; RADIOACTIVITY;

ACTINIUM; BISMUTH; RADIOISOTOPE;

ACTINIUM; ALPHA PARTICLES; BISMUTH; ISOTOPE LABELING; NUCLEAR MEDICINE; RADIOISOTOPES; RADIONUCLIDE GENERATORS;

ACTINIUM; ALPHA PARTICLES; ANTIBODIES; BISMUTH; IMMUNOLOGY; RADIATION CHEMISTRY; RADIATION DAMAGE; RADIATION PROTECTION; RADIOACTIVE TRACERS; RADIOTHERAPY;

ANTIBODY LABELING; RADIOIMMUNOTHERAPY;

RADIOISOTOPES;

EID: 0032589014     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8043(98)00151-1     Document Type: Article

References (19)

1. 224Ra Appl. Radiat. Isot. 39:1988;283.
2. -. J. Am. Chem. Soc. 73:1951;1842.
3. 213Bi for alpha-particle-mediated radioimmunotherapy J. Label. Compds. Radiopharm. 40:1997;341.
4. Caron P.C., Co M.S., Bull M.K., Avdalovic N.M., Queen C., Scheinberg D.A. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 52:1992;6761.
5. Chang, J., 1996. Table of the Nuclides. http://necs01.dne.bnl.gov/CoN/index.html.
6. 213Bi production and use as a targeted therapeutic radiopharmaceutical J. Label. Compds. Radiopharm. 40:1997;293.
7. Friedlander, G., Kennedy, J.W., Macias, E.S., Miller, J.M., 1981. Nuclear and Radiochemistry, 3rd ed. John Wiley and Sons, New York.
8. Gangwer, T.E., Goldstein, M., Pillay, K.K.S., 1977. Radiation Effects on Ion Exchange Materials. BNL 50781.
9. 225Ac as a source of α-particles in radioimmunotherapy Nucl. Med. Comm. 14:1993;121.
10. 213Bi -HuM195 (anti-CD33) Blood. 90(suppl):1997;504a.
11. McDevitt M.R., Nikula T.N., Finn R.D., Curcio M.J., Gansow O.A., Geerlings M.W. Sr., Larson S.M., Scheinberg D.A. Bismuth labeled antibodies for therapy of leukemias, lymphomas and carcinomas: preclinical studies. Tumor Targeting. 2(3):1996;182.
12. Murfin P.A. A demonstration of radiation chemical phenomena. J. Inst. Sci. Techn. 5(4):1959;10.
13. Nikula T.K., Curcio M.J., Brechbiel M.W., Gansow O.A., Finn R.D., Scheinberg D.A. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl. Med. Biol. 22:1995;387.
14. Nikula, T.N., McDevitt, M.R., Finn, R.D., Wu, C., Kozak, R.W., Garmestani, K., Brechbiel, M.W., Curcio, M.J., Pippin, C.G., Tiffany-Jones, L., Geerlings, M.W. Sr., Apostolidis, C., Molinet, R., Gansow, O.A., Scheinberg, D.A., 1998. Pharmacokinetics, bioactivity, toxicity, and chemistry of bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies for alpha particle therapy of myeloid leukemias. J. Nucl. Med., in press.
15. Sigalla J., Herbo C. Cinetique et mecanisme de l'oxydation de l'iodure par l'oxygene dissous. J. Chim. Phys. 54:1957;733.
16. Spivakov B.Y., Stoyanov E.S., Gribov L.A., Zolotov Y.A. Raman laser spectroscopic studies of bismuth(III) halide complexes in aqueous solutions. J. Inorg. Nucl. Chem. 41:1979;453.
17. Van Geel, J.N.C., Fuger, J., Koch, L., 1994. Verfahren zur erzeugung von actinium-225 und wismuth-213 European Patent No. 0 443 479 B1.
18. 213Bi for alpha immunotherapy. ITU Annual Report 1995 (EUR 16368), Basic Actinide Research 55.
19. Wu, C., Brechbiel, M.W., Gansow, O.A., 1996. Abstracts of Papers of the American Chemical Society 212(1), 61-NUCL.